Nasdaq: $29.19 (-0.44) | AIM: £4.04 (-0.34)
搜索
新聞檔案

通過選擇所需的新聞類型，可以獲得最新的公告或演示文稿。

請使用 「新聞主題」進一步挑選公告類別。

所有公告的全文可以PDF文件的形式下載。 為方便起見，某些公告的部分或全部文字內容以網頁的方式呈現。 如存有任何不一致之處，請以PDF版本為準。

新聞類型
演示文稿
監管信息公告
新聞主題
其他業務
監管通知
腫瘤學 / 免疫學
集團
找到相關結果： 22
其他業務, 新聞稿, 監管信息公告 | 2020-06-11

和黃醫藥宣佈9500萬美元的廣州市土地收儲補償協議
倫敦：2020年 6月9日，星期二：和黃中國醫藥科技有限公司（簡稱「和黃醫藥」或「Chi-Med」）（納斯達克/倫敦證交所：HCM）宣佈，由其與廣州白雲山醫藥集團股份有限公司各出資50% 成立的
閱讀更多
下載新聞稿 (PDF)
其他業務, 新聞稿, 監管信息公告 | 2016-10-31

Chi-Med Commercial Platform Joint Venture Receives US$59.5 Million Land Compensation Payment
Shanghai agreement triggers a one-time gain to Chi-Med of US$38.2 million in Q4 2016 Shanghai factory relocation complete: now operational with three-fold increase in capacity Cash from Chi-Med Commercial Platform supports developmen
閱讀更多
其他業務, 新聞稿, 監管信息公告 | 2015-12-09

US$105 million Shanghai land compensation agreement
Press Release London: Wednesday, 9 December 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Shanghai Hutchison Pharmaceuticals Limited (“SHPL”), its 50:50 joint venture with a subsidiary of Shanghai Pharma
閱讀更多
其他業務, 監管信息公告 | 2015-07-17

20-year invention patent granted on Chi-Med's best selling prescription drug
London: Friday, 17 July 2015: Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) today announces that Shanghai Hutchison Pharmaceuticals Limited ("SHPL"), its prescription drug joint venture, has been granted an invention patent in China ("Inven
閱讀更多
其他業務, 新聞稿, 監管信息公告 | 2015-01-29

Hutchison Sinopharm and AstraZeneca China signed an exclusive distribution agreement on Seroquel® in China
Press Release -  London: Thursday, 29 January 2015: Chi-Med, the pharmaceutical and healthcare company based primarily in China, today announces that Hutchison Whampoa Sinopharm Pharmaceuticals (Shanghai) Company Limited ("Hutchison Sinopharm"),
閱讀更多
其他業務, 新聞稿, 監管信息公告 | 2014-10-01

Chi-Med and Merck Serono sign co-promotion agreement
Press Release -  London: Wednesday, 1 October 2014: Chi-Med, the pharmaceutical and healthcare company based primarily in China, today announces that Chi-Med, through its subsidiary Hutchison Whampoa Sinopharm Pharmaceuticals (Shanghai) Company L
閱讀更多
其他業務, 監管信息公告 | 2014-05-30

Chi-Med and Shanghai Traditional Chinese Medicine expand commercial cooperation
其他業務, 監管信息公告 | 2014-04-17

Chi-Med and Sinopharm complete regulatory approval for the establishment of new China drug distribution and marketing Joint Venture
其他業務, 監管信息公告 | 2013-12-18

Chi-Med and Sinopharm form China drug distribution and marketing joint venture
其他業務, 監管信息公告 | 2011-07-22

China Healthcare Division expands OTC drug distribution and marketing operations
其他業務, 監管信息公告 | 2010-12-10

China Healthcare Division Chi-Med increases indirect ownership of its Hutchison Baiyunshan joint venture
其他業務, 監管信息公告 | 2010-09-20

Hutchison Hain Organic launch EARTH'S BEST® and ZHI LING TONG Co-branded Infant formula in China
其他業務, 監管信息公告 | 2010-04-19

Seven-year extension of IP protection for Chi-Med's main prescription drug
其他業務, 監管信息公告 | 2010-01-19

Three more of Chi-Med's China Healthcare Division drugs added to latest China's National Medicines Catalogue
其他業務, 監管信息公告 | 2009-10-26

Chi-Med increases ownership of its Hutchison Healthcare joint venture to 100%
其他業務, 監管信息公告 | 2009-10-16

Newly Published China National Essential Medicines List Reference Prices No Overall Negative Impact on Chi-Med Prices
其他業務, 監管信息公告 | 2009-10-08

Chi-Med announces joint venture with The Hain Celestial Group to develop natural and organic consumer products in Asia
其他業務, 監管信息公告 | 2009-08-27

Chi-Med's Main Drugs Included in the New National Essential Medicines List
其他業務, 監管信息公告 | 2008-05-23

China Healthcare Division Chi-Med increases ownership of its Hutchison Healthcare joint venture
其他業務, 監管信息公告 | 2008-05-19

Expansion of Consumer Products division Sen launches in 125 Marionnaud beauty stores
其他業務, 監管信息公告 | 2008-01-21

Strong growth in China Healthcare divisionStreamlining of product range set to further improve financial performance
其他業務, 監管信息公告 | 2007-01-17

Related party transaction Chi-Med formalises China Sales and Distribution Arrangements